DEERFIELD, Ill. / Jan 02, 2025 / Business Wire / Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Friday, January 10, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.
The company today announced it is moving the previously scheduled earnings date of January 9 back one day, as the Securities and Exchange Commission and U.S. stock markets will be closed on the 9th in observance of a national day of mourning for former President Jimmy Carter.
The earnings conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call.
About Walgreens Boots Alliance
Walgreens Boots Alliance (Nasdaq: WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 175-year heritage of caring for communities.
A trusted, global innovator in retail pharmacy with approximately 12,500 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. Through dispensing medicines, improving access to pharmacy and health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare in the thousands of communities it serves and beyond.
WBA employs approximately 312,000 people, with a presence in eight countries and consumer brands including: Walgreens, Boots, Duane Reade, No7 Beauty Company and Benavides. The Company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. In fiscal 2024, WBA scored 100% on the Disability Equality Index for disability inclusion.
More Company information is available at www.walgreensbootsalliance.com.
| Last Trade: | US$11.74 |
| Daily Change: | 0.12 1.03 |
| Daily Volume: | 17,383,378 |
| Market Cap: | US$10.150B |
January 10, 2025 December 13, 2024 October 15, 2024 October 07, 2024 August 19, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
